This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up.

Core Insights - Investors anticipate a significant increase in deal activity in 2026 as pharmaceutical companies aim to replenish their pipelines and take advantage of low interest rates [1] Industry Summary - Drug makers are expected to engage in more mergers and acquisitions to enhance their product offerings and ensure future growth [1] - The current low interest rate environment is seen as a favorable condition for financing new deals, encouraging companies to pursue strategic transactions [1]